FDA rejects liver cancer drug combo, shares of Korean biotech tank

Ko­re­an biotech HLB and its Chi­na-based part­ner Jiang­su Hen­grui Phar­ma­ceu­ti­cals said Fri­day that the FDA re­ject­ed their drug com­bi­na­tion for the most com­mon form of liv­er can­cer.

The FDA re­ject­ed the pair­ing of rivo­ceranib and cam­re­lizum­ab as a first-line treat­ment for pa­tients with un­re­sectable he­pa­to­cel­lu­lar car­ci­no­ma. The US reg­u­la­tor had set a de­ci­sion dead­line of this month for the small mol­e­cule ty­ro­sine ki­nase in­hibitor rivo­ceranib and the an­ti-PD-1 cam­re­lizum­ab. Chi­na’s health au­thor­i­ties green­lit the com­bo in ear­ly 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.